fluorodeoxyglucose f18 has been researched along with sirolimus in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Czernin, J; Hildebrandt, IJ; Phelps, ME; Su, H; Weber, WA; Wei, LH | 1 |
| Endres, C; Hidalgo, M; Jacene, H; Jimeno, A; Laheru, D; Ma, WW; Messersmith, WA; Pomper, MG; Song, D; Vilardell, F; Wahl, R | 1 |
| Cejka, D; Fritzer-Szekeres, M; Fueger, BJ; Fuereder, T; Kuntner, C; Langer, O; Mueller, M; Preusser, M; Strommer, S; Wacheck, V; Wanek, T; Werzowa, J; Zsebedics, M | 1 |
| Brepoels, L; De Groot, T; De Wolf-Peeters, C; Mortelmans, L; Stroobants, S; Verhoef, G | 1 |
| Bangard, C; Boellaard, R; Dietlein, M; Dimitrijevic, S; Eschner, W; Giaccone, G; Gross, SH; Hayes, W; Hoekstra, OS; Hoetjes, N; Kobe, C; Lammertsma, AA; Nogová, L; Pellas, T; Schmidt, K; Thomas, RK; Wolf, J; Zander, T | 1 |
| Amadori, D; De Giorgi, U | 1 |
| Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W | 1 |
| Bellan, E; Biasco, G; Boschi, S; Castelli, M; Castellucci, P; Di Battista, M; Fanti, S; Gnocchi, C; Landuzzi, L; Lollini, PL; Nanni, C; Nannini, M; Nicoletti, G; Pantaleo, MA; Quarta, C; Rubello, D | 1 |
| Brouwers, AH; de Vries, EG; Fiebrich, HB; Hospers, GA; Links, TP; Remkes, WS; Siemerink, EJ | 1 |
| Aichler, M; Baumgart, A; Buck, A; Dechow, T; Feuchtinger, A; Graf, N; Herrmann, K; Jünger, A; Keller, U; Li, Z; Peschel, C; Schwaiger, M; Walch, A | 1 |
| Albrecht, D; Clipson, L; Deming, DA; Farhoud, M; Halberg, RB; Leystra, AA; Nettekoven, L; Sullivan, R; Washington, MK; Weichert, JP | 1 |
| Avadhani, AN; Ciunci, CA; Divgi, CR; Englander, S; Flaherty, KT; Giantonio, BJ; Harlacker, K; Kang, HC; O'Dwyer, PJ; Perini, RF; Redlinger, M; Rosen, MA; Schnall, M; Song, HK; Sun, W; Troxel, A | 1 |
| Appelbaum, DE; Chen, JL; Cowey, CL; Kocherginsky, M; McDermott, DF; Rathmell, WK; Stadler, WM | 1 |
| Boers-Sonderen, MJ; de Geus-Oei, LF; Desar, IM; Ottevanger, PB; Oyen, WJ; van der Graaf, WT; van Herpen, CM | 1 |
| Boerman, OC; Fleuren, ED; Flucke, UE; Franssen, GM; Houghton, PJ; Oyen, WJ; Roeffen, MH; van der Graaf, WT; Versleijen-Jonkers, YM | 1 |
| Alavi, A; Algazy, KM; Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Heitjan, DF; Hu, J; Kaiser, J; O'Dwyer, PJ; Panosian, JT; Pontiggia, L; Rangwala, R; Redlinger, M; Schuchter, LM; Tan, KS; Torigian, DA; Troxel, AB; Vaughn, DJ | 1 |
| Han, J; Hou, G; Liang, T; Song, J; Sun, H; Yang, G; Zhang, C | 1 |
| Bang, YJ; Cho, BC; Chung, JS; Han, JY; Kang, JH; Kim, DW; Kim, H; Kim, MJ; Kwon, JH; Oh, DY; Park, KU; Shin, SH | 1 |
| Abu-Khalaf, MM; Azodi, M; Baumgart, MA; Chen, N; Deshpande, H; Digiovanna, MP; Doddamane, I; Gettinger, SN; Harris, LN; Hatzis, C; Hou, S; Lezon-Geyda, K; Schwartz, PE; Sullivan, C; Tuck, DP; Zelterman, D | 1 |
| Chen, YK; Chi, KH; Chi, MS; Chung, CH; Huang, SC; Ko, HL; Lee, CY; Liao, KW; Yang, KL | 1 |
| Cheng, D; Hou, G; Liu, H; Ma, Y; Sun, H; Wang, H; Wang, K; Yang, N; Zhang, C | 1 |
| Becher-Boveleth, N; Bockisch, A; Broecker-Preuss, M; Dührsen, U; Müller, S | 1 |
| Albaiz, F; Alothman, B; Alrasheedi, S; Saleemi, A; Saleemi, S; Shah, YZ | 1 |
10 trial(s) available for fluorodeoxyglucose f18 and sirolimus
| Article | Year |
|---|---|
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Mice; Mice, Nude; Neoplasms; Patient Selection; Phosphorylation; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinases; Proto-Oncogene Proteins c-akt; Radiopharmaceuticals; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2009 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Everolimus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sirolimus; Temozolomide | 2011 |
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Sirolimus; Treatment Outcome; Tumor Burden | 2013 |
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Middle Aged; Multimodal Imaging; Ovarian Neoplasms; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2014 |
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Vacuoles | 2014 |
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Sirolimus; Treatment Outcome; Tumor Burden | 2014 |
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Blood Glucose; Drug Administration Schedule; Exanthema; Female; Fluorodeoxyglucose F18; Humans; Hydroxychloroquine; Male; Middle Aged; Nausea; Positron-Emission Tomography; Sarcoma; Sirolimus; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
14 other study(ies) available for fluorodeoxyglucose f18 and sirolimus
| Article | Year |
|---|---|
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Glucose; Humans; Mice; Positron-Emission Tomography; Protein Kinases; Sirolimus; Thymidine; Thymidine Kinase; TOR Serine-Threonine Kinases; Tyrosine | 2008 |
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carrier Proteins; Cell Line, Tumor; Enzyme Inhibitors; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cyclophosphamide; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphoma; Metabolic Clearance Rate; Mice; Mice, SCID; Protein Kinase Inhibitors; Protein Kinases; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Treatment Outcome | 2009 |
[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
Topics: Antibiotics, Antineoplastic; Disease Progression; Disease-Free Survival; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Enzyme Inhibitors; Everolimus; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Knockout; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Receptor, Platelet-Derived Growth Factor alpha; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Blood Glucose; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Hypoglycemia; Insulin; Insulin Secretion; Insulinoma; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases | 2011 |
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Dideoxynucleosides; Enzyme Inhibitors; Everolimus; Female; Flow Cytometry; Fluorine Radioisotopes; Fluorodeoxyglucose F18; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large-Cell, Anaplastic; Mice; Mice, SCID; Positron-Emission Tomography; Protein-Tyrosine Kinases; Resorcinols; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.
Topics: Animals; Apoptosis; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Colon; Colonic Neoplasms; Fluorodeoxyglucose F18; Humans; Male; MAP Kinase Signaling System; Mice; Multimodal Imaging; Necrosis; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases | 2013 |
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Non-invasive imaging of allogeneic transplanted skin graft by 131I-anti-TLR5 mAb.
Topics: Allografts; Animals; Antibodies, Monoclonal; Autoradiography; Diagnostic Imaging; Fluorodeoxyglucose F18; Immunohistochemistry; Immunosuppressive Agents; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Reproducibility of Results; Sirolimus; Skin Transplantation; Tissue Distribution; Toll-Like Receptor 5; Transplantation, Homologous | 2014 |
Anti‑migratory effect of rapamycin impairs allograft imaging by 18F‑fluorodeoxyglucose‑labeled splenocytes.
Topics: Allografts; Animals; Autoradiography; Cell Movement; Cell Tracking; Female; Fluorodeoxyglucose F18; Lymphocytes; Mice; Models, Animal; Sirolimus; Spleen | 2016 |
Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Topics: Cell Line, Tumor; Cell Survival; Chromones; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Inhibitory Concentration 50; Lymphoma; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-myc; Sirolimus; Time Factors | 2017 |
Role of Fluorodeoxyglucose Positron Emission Tomogram Scan in Sirolimus-Induced Lung Toxicity: A Rare Case Report.
Topics: Aged; Drug Substitution; Fluorodeoxyglucose F18; Humans; Immunosuppressive Agents; Kidney Transplantation; Living Donors; Lung; Male; Pneumonia; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sirolimus; Tacrolimus; Treatment Outcome | 2020 |